<bill session="115" type="h" number="5247" updated="2019-04-18T16:21:06Z">
  <state datetime="2018-03-21T21:54:18-04:00">PASS_OVER:HOUSE</state>
  <status>
    <unknown datetime="2018-03-21T21:54:18-04:00"/>
  </status>
  <introduced datetime="2018-03-13"/>
  <titles>
    <title type="official" as="introduced">To authorize the use of eligible investigational drugs by eligible patients who have been diagnosed with a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months, or with another eligible illness, and for other purposes.</title>
    <title type="short" as="passed house">Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018</title>
    <title type="short" as="passed house">Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018</title>
    <title type="short" as="introduced">Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018</title>
    <title type="short" as="introduced">Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018</title>
    <title type="display">Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018</title>
  </titles>
  <sponsor bioguide_id="F000466"/>
  <cosponsors>
    <cosponsor bioguide_id="A000372" joined="2018-03-13"/>
    <cosponsor bioguide_id="B001282" joined="2018-03-13"/>
    <cosponsor bioguide_id="B000213" joined="2018-03-13"/>
    <cosponsor bioguide_id="B001302" joined="2018-03-13"/>
    <cosponsor bioguide_id="B001273" joined="2018-03-13"/>
    <cosponsor bioguide_id="B001243" joined="2018-03-13"/>
    <cosponsor bioguide_id="B001274" joined="2018-03-13"/>
    <cosponsor bioguide_id="B001260" joined="2018-03-13"/>
    <cosponsor bioguide_id="B001297" joined="2018-03-13"/>
    <cosponsor bioguide_id="B001248" joined="2018-03-13"/>
    <cosponsor bioguide_id="C000059" joined="2018-03-14"/>
    <cosponsor bioguide_id="C001103" joined="2018-03-13"/>
    <cosponsor bioguide_id="C001092" joined="2018-03-13"/>
    <cosponsor bioguide_id="C001105" joined="2018-03-13"/>
    <cosponsor bioguide_id="C001096" joined="2018-03-13"/>
    <cosponsor bioguide_id="C001048" joined="2018-03-13"/>
    <cosponsor bioguide_id="D000615" joined="2018-03-13"/>
    <cosponsor bioguide_id="D000628" joined="2018-03-13"/>
    <cosponsor bioguide_id="F000464" joined="2018-03-13"/>
    <cosponsor bioguide_id="G000579" joined="2018-03-13"/>
    <cosponsor bioguide_id="G000565" joined="2018-03-13"/>
    <cosponsor bioguide_id="G000568" joined="2018-03-13"/>
    <cosponsor bioguide_id="H001078" joined="2018-03-13"/>
    <cosponsor bioguide_id="H001045" joined="2018-03-13"/>
    <cosponsor bioguide_id="H001053" joined="2018-03-13"/>
    <cosponsor bioguide_id="H001056" joined="2018-03-13"/>
    <cosponsor bioguide_id="H001072" joined="2018-03-13"/>
    <cosponsor bioguide_id="H001058" joined="2018-03-14"/>
    <cosponsor bioguide_id="I000056" joined="2018-03-13"/>
    <cosponsor bioguide_id="K000362" joined="2018-03-13"/>
    <cosponsor bioguide_id="L000564" joined="2018-03-13"/>
    <cosponsor bioguide_id="L000567" joined="2018-03-13"/>
    <cosponsor bioguide_id="L000587" joined="2018-03-13"/>
    <cosponsor bioguide_id="M001198" joined="2018-03-13"/>
    <cosponsor bioguide_id="M001187" joined="2018-03-13"/>
    <cosponsor bioguide_id="M001189" joined="2018-03-13"/>
    <cosponsor bioguide_id="N000189" joined="2018-03-19"/>
    <cosponsor bioguide_id="R000592" joined="2018-03-19"/>
    <cosponsor bioguide_id="R000598" joined="2018-03-13"/>
    <cosponsor bioguide_id="S001183" joined="2018-03-13"/>
    <cosponsor bioguide_id="S001191" joined="2018-03-13"/>
    <cosponsor bioguide_id="W000814" joined="2018-03-13"/>
    <cosponsor bioguide_id="Y000063" joined="2018-03-13"/>
    <cosponsor bioguide_id="Y000065" joined="2018-03-13"/>
  </cosponsors>
  <actions>
    <action datetime="2018-03-13">
      <text>Introduced in House</text>
    </action>
    <action datetime="2018-03-13" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2018-03-13T17:40:04-04:00">
      <text>Mr. Walden moved to suspend the rules and pass the bill.</text>
    </action>
    <action datetime="2018-03-13T17:40:14-04:00">
      <text>Considered under suspension of the rules.</text>
      <reference ref="CR H1521-1527" label="consideration"/>
      <reference ref="CR H1521-1522" label="text of measure as introduced"/>
    </action>
    <action datetime="2018-03-13T17:40:17-04:00">
      <text>DEBATE - The House proceeded with forty minutes of debate on H.R. 5247.</text>
    </action>
    <action datetime="2018-03-13T18:25:52-04:00">
      <text>At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.</text>
    </action>
    <action datetime="2018-03-13T18:29:31-04:00">
      <text>Considered as unfinished business.</text>
      <reference ref="CR H1528-1529" label="consideration"/>
    </action>
    <vote how="roll" type="vote" roll="102" datetime="2018-03-13T18:56:47-04:00" where="h" result="fail" suspension="1" state="PROV_KILL:SUSPENSIONFAILED">
      <text>On motion to suspend the rules and pass the bill Failed by the Yeas and Nays: (2/3 required): 259 - 140 (Roll no. 102).</text>
    </vote>
    <action datetime="2018-03-16">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2018-03-19T19:08:52-04:00">
      <text>Rules Committee Resolution H. Res. 787 Reported to House. The resolution provides for one hour of debate on each bill. The resolution makes in order only the further amendment to H.R. 4566 printed in the report. No further amendments on either bill are made in order. Section 3 of the resolution makes it in order to consider any resolution reported from the Rules Committee on the day it is reported through the legislative day of March 23, 2018. Section 4 grants suspension authority on the legislative days of March 22, 2018 and March 23, 2018. Section 5 of the resolution amends section 3(a) of H. Res. 5.</text>
    </action>
    <action datetime="2018-03-20T14:19:16-04:00">
      <text>Rule H. Res. 787 passed House.</text>
    </action>
    <action datetime="2018-03-21T13:01:32-04:00">
      <text>Considered under the provisions of rule H. Res. 787.</text>
      <reference ref="CR H1738-1748" label="consideration"/>
    </action>
    <action datetime="2018-03-21T13:01:37-04:00">
      <text>The resolution provides for one hour of debate on each bill. The resolution makes in order only the further amendment to H.R. 4566 printed in the report. No further amendments on either bill are made in order. Section 3 of the resolution makes it in order to consider any resolution reported from the Rules Committee on the day it is reported through the legislative day of March 23, 2018. Section 4 grants suspension authority on the legislative days of March 22, 2018 and March 23, 2018. Section 5 of the resolution amends section 3(a) of H. Res. 5.</text>
    </action>
    <action datetime="2018-03-21T13:02:43-04:00">
      <text>DEBATE - The House proceeded with one hour of debate on H.R. 5247.</text>
    </action>
    <action datetime="2018-03-21T13:59:53-04:00">
      <text>The previous question was ordered pursuant to the rule.</text>
    </action>
    <action datetime="2018-03-21T14:00:52-04:00">
      <text>Mr. Pallone moved to recommit with instructions to the Committee on Energy and Commerce.</text>
      <reference ref="CR H1746-1747" label="text"/>
    </action>
    <action datetime="2018-03-21T14:01:07-04:00">
      <text>DEBATE - The House proceeded with 10 minutes of debate on the Pallone motion to recommit with instructions. The instructions contained in the motion seek to report the same back to the House forthwith with an amendment to require the Food and Drug Administration (FDA) to issue guidance describing how the agency will use expanded access outcomes when considering and evaluating investigational products for full approval. Additionally, the motion seeks to provide liability protection to manufacturers, physicians, and hospitals offering a product under expanded access, as long as the entity is in compliance with current federal law, and it also increases transparency in the FDAs expanded access program.</text>
    </action>
    <action datetime="2018-03-21T14:07:51-04:00">
      <text>The previous question on the motion to recommit with instructions was ordered without objection.</text>
    </action>
    <action datetime="2018-03-21T14:08:01-04:00">
      <text>POSTPONED PROCEEDINGS - At the conclusion of debate on the Pallone motion to recommit with instructions, the Chair put the question on the motion and by voice vote announced that the ayes had prevailed. Mr. Pallone demanded the yeas and nays, and the Chair postponed further proceedings on the motion to recommit until later in the legislative day.</text>
    </action>
    <action datetime="2018-03-21T21:16:16-04:00">
      <text>Considered as unfinished business.</text>
      <reference ref="CR H1748-1750" label="consideration"/>
    </action>
    <action datetime="2018-03-21T21:44:35-04:00">
      <text>On motion to recommit with instructions Failed by the Yeas and Nays: 182 - 233 (Roll no. 120).</text>
    </action>
    <vote how="roll" type="vote" roll="121" datetime="2018-03-21T21:54:18-04:00" where="h" result="pass" state="PASS_OVER:HOUSE">
      <text>On passage Passed by recorded vote: 267 - 149 (Roll no. 121).</text>
      <reference ref="CR H1738-1739" label="text"/>
    </vote>
    <action datetime="2018-03-21T21:54:20-04:00">
      <text>Motion to reconsider laid on the table Agreed to without objection.</text>
    </action>
    <action datetime="2018-03-22">
      <text>Received in the Senate.</text>
    </action>
    <action datetime="2018-03-23">
      <text>Read the first time. Placed on Senate Legislative Calendar under Read the First Time.</text>
    </action>
    <calendar datetime="2018-04-09" calendar="Senate Legislative" under="General Orders" number="367">
      <text>Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 367.</text>
    </calendar>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
    <committee subcommittee="Health" code="HSIF14" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="s" session="115" relation="unknown" number="204"/>
    <bill type="hr" session="115" relation="procedurally-related" number="787"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Business records"/>
    <term name="Civil actions and liability"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Government information and archives"/>
    <term name="Long-term, rehabilitative, and terminal care"/>
    <term name="Medical research"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <committee-reports/>
</bill>
